Oculopharyngeal Muscular Dystrophy

1. Disease Information

Overview

Oculopharyngeal muscular dystrophy (OPMD) is a rare, autosomal dominant (rarely recessive) late-onset progressive muscular dystrophy characterized by the classical triad of progressive bilateral ptosis, dysphagia, and proximal limb weakness. Onset typically occurs in the fifth or sixth decade of life. OPMD is caused by short GCN trinucleotide repeat expansions in the polyadenylate-binding protein nuclear 1 (PABPN1) gene, encoding an expanded polyalanine tract in the PABPN1 protein (Brais et al., 1998, PMID: 9462747).

Key Identifiers

• MONDO: MONDO:0008116
• OMIM: #164300 (autosomal dominant); #257950 (autosomal recessive form)
• Orphanet: ORPHA:270 (autosomal dominant), ORPHA:270 (recessive)
• ICD-10: G71.0 (Muscular dystrophy)
• ICD-11: 8C70.0 (Autosomal dominant muscular dystrophies)
• MeSH: D039141 (Muscular Dystrophy, Oculopharyngeal)
• HGNC gene: PABPN1 (HGNC:8565)
• UniProt (PABPN1): Q86U42

Synonyms and Alternative Names

• OPMD
• Progressive oculopharyngeal muscular dystrophy
• Oculopharyngeal dystrophy
• Muscular dystrophy, oculopharyngeal type
• Taylor's disease (historical, after Edward Taylor's 1915 description of a French-Canadian family; Taylor EW, 1915)
• French-Canadian oculopharyngeal muscular dystrophy (historical, related to founder effect)

Information Sources

Information is derived from a combination of: - Individual patient case series and multicenter cohorts (including French-Canadian, Bukhara Jewish, Uruguayan, French, and international cohorts) - Aggregated disease-level resources (OMIM, Orphanet, GeneReviews, Neuromuscular Disease Center at Washington University) - Muscle biopsy pathology databases - Genetic testing registries (ClinVar, GTR)

Key references: - Brais B, et al. Nat Genet. 1998;18(2):164-167. PMID: 9462747 (original discovery of PABPN1 mutations) - Trollet C, et al. GeneReviews. Updated 2020. PMID: 20301305 - Van der Sluijs BM, et al. J Neurol Neurosurg Psychiatry. 2016;87(4):448-450. PMID: 25990033 - Richard P, et al. J Med Genet. 2017;54(3):151-157. PMID: 27831907

2. Etiology

Disease Causal Factors

Primary cause: Genetic (autosomal dominant, rarely recessive)

OPMD is caused by an expansion of a GCN (predominantly GCG) trinucleotide repeat in exon 1 of the PABPN1 gene, located at chromosome 14q11.2. The normal allele contains 10 GCN repeats [(GCG)6(GCA)3GCG], encoding a stretch of 10 alanines at the N-terminus of PABPN1. Expansions of the (GCG)6 to (GCG)8-13 lead to expanded polyalanine tracts of 11-18 alanines, causing autosomal dominant OPMD (Brais et al., 1998, PMID: 9462747).

Original discovery quote: "Short (GCG)8-13 expansions of a (GCG)6 repeat in the PABP2 gene cause autosomal dominant oculopharyngeal muscular dystrophy (OPMD), whereas a longer (GCG)7 allele acts as a recessive mutation" (Brais et al., 1998, PMID: 9462747).

Genetic Risk Factors

Causal variants: - Expanded (GCN)11-18 tract in PABPN1 (autosomal dominant) - Homozygous (GCN)11 (GCG7 homozygous) or compound heterozygous (autosomal recessive form, typically milder or with later onset) - ClinVar Variation ID for GCN expansion: multiple entries under PABPN1

Modifier alleles: - Homozygosity for the expanded allele results in a more severe phenotype with earlier onset (Blumen et al., 1999, PMID: 10023876). - Compound heterozygosity with the (GCN)11 allele on the second chromosome can act as a modifier, accelerating disease onset (Semmler et al., 2007, PMID: 17761685).

Environmental Risk Factors

• Age is the strongest non-genetic risk factor: penetrance approaches 100% by age 70 in carriers of the dominant expansion.
• No confirmed lifestyle, occupational, or environmental triggers have been established.

Protective Factors

• Genetic: No confirmed protective variants; however, shorter alanine tract lengths (i.e., normal 10 alanines) confer no disease risk.
• Environmental: No established environmental protective factors. Some evidence suggests physical activity may help maintain function in symptomatic patients (Trollet C et al., 2020 GeneReviews).

Gene-Environment Interactions

• No robust gene-environment interactions have been characterized for OPMD.
• Chronic mechanical stress on ocular and pharyngeal muscles may contribute to preferential involvement of these muscle groups, but this has not been experimentally proven (Trollet et al., 2010, PMID: 20876750).

3. Phenotypes

Core Clinical Triad

1. Ptosis (bilateral, progressive) - HPO term: HP:0000508 (Ptosis) - Type: Physical manifestation (clinical sign) - Age of onset: Typically 4th-6th decade (mean ~48 years; typically first symptom) - Frequency: ~100% of symptomatic patients - Severity: Progressive; often requires eyelid surgery - Quality of life impact: Impaired vision, compensatory head extension leading to cervical pain - Evidence: Brais B et al., 1998, PMID: 9462747; Trollet C et al., GeneReviews, 2020

2. Dysphagia (progressive difficulty swallowing) - HPO term: HP:0002015 (Dysphagia) - Type: Symptom / clinical sign - Age of onset: 5th-6th decade (usually follows ptosis by several years; some patients have dysphagia first) - Frequency: ~100% of affected individuals eventually - Severity: Progressive; can lead to aspiration pneumonia and malnutrition - Quality of life impact: Major impact — dietary modifications, weight loss, aspiration risk, social withdrawal from meals - Evidence: Brais B et al., 1998, PMID: 9462747; Périé S et al., 2011, PMID: 21316014

3. Proximal limb weakness - HPO term: HP:0003701 (Proximal muscle weakness) - Type: Physical manifestation - Age of onset: Later than ptosis and dysphagia (typically 6th-7th decade); lower limbs affected earlier than upper - Frequency: ~60-80% in advanced disease - Severity: Slow progression; loss of ambulation in ~10-25% at late stages - Quality of life impact: Ambulation difficulty, falls, dependence - Evidence: Van der Sluijs BM et al., 2016, PMID: 25990033

Additional Phenotypes

Facial muscle weakness - HPO term: HP:0000317 (Facial hypotonia) / HP:0010628 (Facial palsy) - Frequency: ~40-50% (usually mild)

Ophthalmoplegia (external) - HPO term: HP:0000602 (Ophthalmoplegia) / HP:0000544 (External ophthalmoplegia) - Frequency: ~30-50%; usually mild-moderate limitation of extraocular movements - Onset: Later than ptosis; typically after age 50 - Evidence: Trollet C et al., GeneReviews; Semmler A et al., 2007

Dysphonia (nasal or hoarse voice) - HPO term: HP:0001618 (Dysphonia) - Frequency: ~50-70% due to pharyngeal muscle involvement

Tongue atrophy and weakness - HPO term: HP:0000198 (Tongue atrophy) - Frequency: Common in advanced disease

Aspiration pneumonia - HPO term: HP:0011951 (Aspiration pneumonia) - Frequency: Major cause of morbidity/mortality; recurrent episodes common in late disease

Weight loss / malnutrition - HPO term: HP:0001824 (Weight loss) - Secondary to dysphagia

Neck flexor weakness - HPO term: HP:0003722 (Neck flexor weakness) - Frequency: ~50% in advanced disease

Muscle biopsy findings (pathological phenotype): - Intranuclear inclusions in muscle nuclei (pathognomonic ultrastructural finding) - HPO term: Not directly represented; described as "rimmed vacuoles" (HP:0003798) - Rimmed vacuoles present in ~4-5% of muscle fibers

Onset Summary

• Presenting symptom in ~80% of cases: ptosis
• Presenting symptom in ~20% of cases: dysphagia
• Mean age of onset: ~48-53 years for autosomal dominant OPMD (Brais et al., 1998; Richard et al., 2017)

4. Genetic/Molecular Information

Causal Gene

PABPN1 (Polyadenylate-Binding Protein Nuclear 1) - HGNC: hgnc:8565 - Chromosome: 14q11.2 - OMIM Gene: 602279 - NCBI Gene: 8106 - UniProt: Q86U42 - Protein: Nuclear poly(A) binding protein 1 (PABPN1); previously called PABP2

Pathogenic Variant Type

GCN trinucleotide repeat expansion in exon 1 of PABPN1 - Normal allele: (GCN)10 encoding 10 alanines [(GCG)6(GCA)3GCG] - Autosomal dominant OPMD: (GCN)11-18 (expanded polyalanine tract of 11-18 alanines) - Autosomal recessive OPMD: Two (GCN)11 alleles (mildest form) - Compound (GCN)11 with expanded allele: More severe phenotype (Semmler et al., 2007, PMID: 17761685)

Variant Classification (ACMG/AMP): - Pathogenic — established mutation mechanism

Functional Consequences: - Toxic gain of function through expanded polyalanine tract - Formation of insoluble intranuclear PABPN1 aggregates in muscle nuclei (Calado A et al., 2000, PMID: 11003708) - Impaired poly(A) tail regulation, mRNA processing, alternative polyadenylation site selection (Jenal M et al., 2012, PMID: 22579045)

Allele Frequency

• Expanded PABPN1 alleles are rare in gnomAD; carrier frequency varies:
• French-Canadian population (Quebec): ~1 in 1,000 (founder effect; Brais et al., 1995, PMID: 8580435)
• Bukhara Jews in Israel: ~1 in 600 (founder effect; Blumen et al., 1997)
• General populations: ~1 in 100,000 to 1 in 200,000

Somatic vs Germline Origin

• Germline: All pathogenic PABPN1 expansions are germline; somatic mutations are not a mechanism.

Modifier Genes

• No robust modifier genes have been identified beyond PABPN1 allelic variation itself.
• HSPA1A/HSPB5 (heat shock proteins) may modify aggregate formation in vitro (Bao YP et al., 2002, PMID: 12403780).

Epigenetic Information

• No established DNA methylation or histone modification changes specifically linked to OPMD pathogenesis.
• Aging-related epigenetic drift may influence age-dependent penetrance (speculative).

Chromosomal Abnormalities

• No large chromosomal abnormalities associated with OPMD; disease is caused exclusively by trinucleotide repeat expansions in PABPN1.

5. Environmental Information

Environmental Factors

• No definitive environmental toxins, radiation, or pollution are known to cause or exacerbate OPMD.
• Chronic mechanical use of extraocular and pharyngeal muscles may contribute to selective vulnerability (unproven).

Lifestyle Factors

• No confirmed lifestyle factors (smoking, alcohol, diet) modify OPMD risk or progression.
• Aspiration risk is exacerbated by supine positioning and rapid eating; behavioral modifications (upright eating, texture-modified diets) are used clinically.

Infectious Agents

• Not applicable. OPMD is not caused or triggered by pathogens.

6. Mechanism / Pathophysiology

Ordered Causal Chain

1. Germline (GCN)11-18 trinucleotide repeat expansion in PABPN1 exon 1 → generates mRNA encoding PABPN1 with an expanded N-terminal polyalanine tract (11-18 alanines instead of 10).

2. Expanded polyalanine tract induces protein misfolding → the expanded PABPN1 (expPABPN1) protein misfolds and self-associates into insoluble oligomers (Calado A et al., 2000, PMID: 11003708).

3. Formation of pathognomonic intranuclear inclusions (INIs) in skeletal muscle nuclei → insoluble aggregates of expPABPN1 accumulate as filamentous nuclear inclusions, ~8.5 nm in diameter, containing polyadenylated RNA, ubiquitin, proteasomal subunits, HSP70, and other nuclear proteins (Tomé & Fardeau, 1980; Calado A et al., 2000).

4. Sequestration of nuclear proteins and RNA → INIs sequester poly(A) mRNA, functional PABPN1, HSPs, ubiquitin/proteasome components, and transcription factors, causing partial loss of PABPN1 function and impaired mRNA metabolism (Corbeil-Girard LP et al., 2005, PMID: 15721219).

5. Alternative polyadenylation site dysregulation → PABPN1 loss of function shifts alternative polyadenylation (APA) site usage, causing widespread transcriptomic dysregulation (proximal APA site preference, transcript shortening) (Jenal M et al., 2012, PMID: 22579045; de Klerk E et al., 2012, PMID: 22821563).

6. Proteostasis stress → chronic aggregate burden and impaired proteasome function activate the unfolded protein response and autophagy pathways; aggregate-mediated toxicity impairs cellular homeostasis (Abu-Baker A et al., 2003, PMID: 14507991).

7. Cellular stress responses in muscle fibers → mitochondrial dysfunction, oxidative stress, and abnormal RNA processing lead to sarcomere protein turnover imbalance and impaired protein synthesis (Anvar SY et al., 2011, PMID: 21929762).

8. Selective muscle fiber degeneration → myofibers atrophy, undergo apoptosis or necrosis, and are progressively replaced by fibrofatty tissue. Rimmed vacuoles containing autophagic debris form (Tomé & Fardeau, 1980).

9. Preferential involvement of extraocular, levator palpebrae, pharyngeal, and cricopharyngeal muscles → these muscles have distinct developmental origins, satellite cell populations, and calcium handling that render them particularly vulnerable (Randolph ME & Pavlath GK, 2015; Périé S et al., 2011, PMID: 21316014).

10. Clinical manifestations → progressive ptosis (levator palpebrae dysfunction), dysphagia (cricopharyngeal muscle dysfunction), proximal limb weakness (later, quadriceps and other proximal muscles).

Molecular Pathways Involved

• Pre-mRNA 3′-end processing / polyadenylation (KEGG: hsa03015 mRNA surveillance pathway; Reactome: R-HSA-72187 mRNA 3'-end processing)
• Alternative polyadenylation regulation
• Ubiquitin-proteasome system (impaired clearance of aggregates)
• Autophagy pathway (KEGG: hsa04140)
• Unfolded protein response (partial activation)
• Muscle atrophy signaling (FOXO/atrogin-1/MuRF-1)

Cellular Processes

• Protein aggregation (GO:0043523 regulation of neuron apoptotic process — analogous to muscle)
• Nuclear body formation (GO:0016604 nuclear body)
• mRNA polyadenylation (GO:0006378 mRNA polyadenylation)
• Autophagy (GO:0006914)
• Apoptosis (GO:0006915) — in affected fibers
• Satellite cell dysfunction (impaired regenerative capacity; Périé et al., 2006; Wang Q et al., 2020, PMID: 32348770)

Protein Dysfunction

• PABPN1 (UniProt Q86U42): Normally a nuclear protein regulating poly(A) tail length (adds and stabilizes ~250 nt poly(A) tail on mRNA). Expanded polyalanine tract causes:
• Misfolding and aggregation
• Loss of normal function through sequestration
• Impaired interaction with poly(A) polymerase
• Disruption of PABPN1 nuclear speckle localization

Metabolic Changes

• Muscle atrophy leads to reduced protein synthesis and altered amino acid metabolism.
• Mitochondrial dysfunction observed in muscle biopsies; reduced oxidative phosphorylation capacity (Malerba A et al., 2019, PMID: 30760777).

Immune System Involvement

• No major immune involvement; OPMD is not autoimmune or inflammatory.
• Mild secondary inflammation may occur in degenerating fibers.

Tissue Damage Mechanisms

• Chronic proteotoxic stress from intranuclear aggregates
• Oxidative stress
• Impaired autophagy/proteasome degradation
• Satellite cell exhaustion limiting regeneration
• Progressive fibrosis and fatty replacement

Biochemical Abnormalities

• Serum creatine kinase (CK) may be mildly elevated (1-8× normal) but is often normal.
• Reduced PABPN1 protein levels in affected muscle (due to sequestration in INIs).

Molecular Profiling

Transcriptomics: - Widespread alternative polyadenylation dysregulation in patient muscle biopsies (Jenal et al., 2012, PMID: 22579045) - Quote: "PABPN1 acts as a suppressor of alternative polyadenylation site usage, and its depletion or reduction leads to widespread 3' UTR shortening" (Jenal et al., 2012). - Altered expression of genes involved in muscle contraction, mitochondrial function, and RNA processing (Anvar SY et al., 2013, PMID: 24000905).

Proteomics: - Reduced levels of soluble PABPN1 - Enrichment of ubiquitinated proteins, HSPs, and proteasomal subunits in INI fractions

Advanced Technologies

• Single-cell analysis: Limited studies; satellite cell dysfunction studied in OPMD mouse models (Wang Q et al., 2020, PMID: 32348770).
• iPSC-derived myoblasts: Recapitulate INI formation and mRNA processing defects (Raz V et al., 2013).

7. Anatomical Structures Affected

Organ Level

Primary organs/systems: - Skeletal muscle (musculoskeletal system) — UBERON:0001134 (skeletal muscle tissue) - Eye (indirectly, via levator palpebrae) — UBERON:0000970 - Pharynx — UBERON:0006562

Secondary organs: - Lung (aspiration pneumonia) — UBERON:0002048 - Esophagus / cervical esophagus — UBERON:0001043

Body systems: - Musculoskeletal - Digestive (upper GI due to dysphagia) - Respiratory (secondary due to aspiration)

Tissue and Cell Level

Specific muscles affected (preferential involvement): - Levator palpebrae superioris (ptosis) — UBERON:0011115 - Cricopharyngeal muscle (dysphagia) — UBERON:0006496 - Pharyngeal constrictor muscles — UBERON:0001571 - Extraocular muscles — UBERON:0004264 (skeletal muscle of trunk / eye) - Tongue muscles — UBERON:0001723 - Facial muscles — UBERON:0002376 - Quadriceps femoris (later in disease) — UBERON:0001377 - Iliopsoas (later in disease) - Adductor magnus and hamstrings

Cell types affected: - Skeletal muscle fibers (myofibers): primarily Type 1 (slow-twitch) fibers in most affected muscles — CL:0000188 (skeletal muscle cell) / CL:0008002 (skeletal muscle fiber) - Skeletal muscle satellite cells (impaired regenerative capacity) — CL:0000594 (satellite cell) - Myonuclei (site of PABPN1 intranuclear inclusions) — GO:0005634 (nucleus)

Subcellular Level

Cellular compartments involved: - Nucleus — GO:0005634 (site of PABPN1 intranuclear inclusions) - Nuclear speckles — GO:0016607 (normal PABPN1 localization is disrupted) - Cytoplasm — GO:0005737 (rimmed vacuoles containing autophagic material) - Sarcomere — GO:0030017 (progressive disruption) - Mitochondria — GO:0005739 (secondary dysfunction)

Localization

• Bilateral ptosis (symmetric)
• Bilateral proximal limb weakness
• Selective muscle vulnerability — extraocular, levator palpebrae, pharyngeal, cricopharyngeal, tongue

8. Temporal Development

Onset

• Typical age of onset: 40-60 years (mean ~48-53 years) for autosomal dominant OPMD
• Onset pattern: Insidious, chronic; slowly progressive
• First symptom: Ptosis (~80% of patients); dysphagia (~20%)

Progression

Disease stages (informal clinical classification): 1. Early stage (age 40-55): Onset of ptosis or dysphagia; mild 2. Middle stage (age 55-70): Both cardinal features present; mild proximal weakness; ophthalmoplegia may develop; requires ptosis surgery and dietary modifications 3. Advanced stage (age 70+): Severe dysphagia, potentially requiring cricopharyngeal myotomy or gastrostomy; proximal weakness limits mobility; increased aspiration risk

Progression rate: Slow (over decades); highly variable

Disease course pattern: Steady progressive; no relapsing-remitting or episodic component

Disease duration: Chronic, lifelong

Patterns

• No spontaneous remissions
• No critical intervention windows currently defined
• Treatment (myectomy, cricopharyngeal myotomy) can dramatically improve function for years

Homozygous (recessive) form

• Earlier onset (~40 years)
• More rapid progression
• Higher risk of severe complications

9. Inheritance and Population

Epidemiology

Prevalence: - Worldwide: ~1 in 100,000 (rare) - French-Canadian population (Quebec): ~1 in 1,000 (founder effect; PMID: 8580435) - Bukhara Jews in Israel: ~1 in 600 (founder effect; PMID: 9427262 - Blumen et al., 1997) - Uruguay: Elevated prevalence due to Spanish/Basque ancestry (Medici M et al., 1997) - Netherlands: ~1 in 200,000-250,000 (Van der Sluijs et al., 2003)

Prevalence class (Orphanet): 1-9 / 100,000

Inheritance

• Autosomal dominant (most common form; OMIM 164300)
• Autosomal recessive (rare; OMIM 257950; only with two (GCN)11 alleles)

Penetrance

• Age-dependent penetrance: near-complete by age 70 for dominant expansions
• Onset varies with repeat length: longer expansions → earlier onset

Expressivity

• Variable expressivity, even within families
• Larger expansions → more severe/earlier onset
• Homozygosity for expanded allele → more severe disease

Genetic Anticipation

• No clear anticipation — repeat length is generally stable across generations (Brais et al., 1998, PMID: 9462747)

Germline Mosaicism

• Not a significant feature

Founder Effects

• French-Canadian founder effect: Traced to a single founder couple who immigrated from France to New France in 1634 (Brais et al., 1995, PMID: 8580435)
• Bukhara Jewish founder effect in Israel
• Uruguayan founder effect

Carrier Frequency

• French-Canadians: ~1 in 700
• General populations: ~1 in 100,000

Population Demographics

• Sex ratio: ~1:1 male:female
• Age distribution: Predominantly age 40+; most patients diagnosed after age 50
• Ethnicities with founder effects: French-Canadian, Bukhara Jewish, Hispanic (Uruguay/New Mexico)

10. Diagnostics

Clinical Tests

Laboratory tests: - Serum creatine kinase (CK): Normal to mildly elevated (usually <5× normal) — LOINC: 2157-6

Imaging: - Muscle MRI: Can show selective fatty infiltration of tongue, adductor magnus, hamstrings, quadriceps (later stages); helps assess disease burden - Videofluoroscopic swallowing study (VFSS): Assesses dysphagia severity; shows cricopharyngeal dysfunction, aspiration - FEES (Fiberoptic Endoscopic Evaluation of Swallowing): Assesses swallowing dynamics

Functional tests: - Manometry of upper esophageal sphincter — assesses cricopharyngeal function - Timed swallow tests

Electrophysiology: - EMG: Myopathic pattern (small, short-duration, polyphasic motor unit action potentials) in affected muscles

Biopsy findings (muscle biopsy): - Rimmed vacuoles in myofibers (~4-5% of fibers) - Pathognomonic intranuclear filamentous inclusions (INIs) on electron microscopy — ~8.5 nm filaments in myonuclei - Immunohistochemistry: PABPN1-positive INIs - Loss of oxidative activity in some fibers - Mild variability in fiber size - Rare regenerating fibers

Genetic Testing (GOLD STANDARD)

• Approach: Targeted PABPN1 GCN repeat sizing (PCR + fragment length analysis or Sanger sequencing of exon 1)
• Diagnostic sensitivity: ~100% (all confirmed OPMD cases carry PABPN1 expansions)
• Recommendation: GeneReviews and clinical guidelines recommend PABPN1 gene testing as the first-line diagnostic test in patients with clinical features consistent with OPMD

Clinical Criteria

Diagnostic criteria (Brais et al., 1998; Trollet et al., GeneReviews): - Clinical: Adult-onset progressive ptosis and dysphagia, positive family history (usually), muscle weakness in advanced disease - Molecular: Confirmation of PABPN1 (GCN)11-18 expansion - Muscle biopsy: No longer routinely required after genetic confirmation but can be diagnostic if genetics unavailable

Differential Diagnosis

• Mitochondrial myopathies (CPEO, KSS) — ophthalmoplegia + ptosis; distinguished by mitochondrial DNA analysis, muscle biopsy findings (ragged red fibers)
• Myasthenia gravis — ptosis, dysphagia; distinguished by AChR/MuSK antibodies, decrement on repetitive nerve stimulation, response to edrophonium/pyridostigmine
• Myotonic dystrophy type 1 (DM1) — ptosis, dysphagia; distinguished by myotonia, CTG expansion in DMPK
• Inclusion body myositis (IBM) — dysphagia, proximal + distal weakness; distinguished by muscle biopsy findings, no PABPN1 expansion
• Congenital myasthenic syndromes
• Oculopharyngodistal myopathy (OPDM) — GCN repeats in LRP12, GIPC1, NOTCH2NLC, RILPL1

Screening

• Cascade screening of at-risk family members after proband diagnosis
• Preimplantation genetic diagnosis (PGD) available for at-risk couples
• No population newborn screening (adult-onset)

11. Outcome/Prognosis

Survival and Mortality

• Life expectancy: Near-normal in most cases; slightly reduced in severe/homozygous disease due to aspiration pneumonia
• Disease-specific mortality: Aspiration pneumonia is the leading cause of disease-related death
• 5-year survival: Not significantly reduced
• 10-year survival: Mildly reduced in advanced cases

Morbidity and Function

• Morbidity:
• Chronic ptosis (impaired vision, cosmetic)
• Chronic dysphagia (malnutrition, aspiration)
• Progressive muscle weakness (mobility)
• Recurrent pneumonia
• Disability outcomes:
• ~10-25% of patients become wheelchair-dependent in late disease
• Most require ptosis surgery
• ~30-50% require cricopharyngeal intervention

Quality of Life

• Significant impact due to social effects of dysphagia (avoidance of eating in public), impaired vision from ptosis
• QOL measures show significant impairment in physical and social functioning (Van der Sluijs et al., 2016)

Complications

• Aspiration pneumonia (most serious complication)
• Malnutrition and weight loss
• Falls (due to proximal weakness and impaired vision from ptosis)
• Cervical spine strain (from chin-up posture compensating for ptosis)
• Depression (secondary to disability)

Recovery Potential

• No cure; disease is progressive
• Surgical interventions provide symptomatic improvement (ptosis surgery, cricopharyngeal myotomy)
• Function can be maintained with rehabilitation

Prognostic Factors

• Repeat length: Longer expansions → earlier onset, more severe disease
• Zygosity: Homozygous or compound heterozygous → more severe
• Age at diagnosis: Later diagnosis correlated with more established disease

12. Treatment

No Curative Treatment

OPMD currently has no disease-modifying or curative therapy. All treatments are symptomatic or surgical.

Surgical Interventions

1. Ptosis Surgery (levator resection / frontalis suspension) - NCIT term: NCIT:C15329 (Surgical Procedure) - Most patients require ptosis surgery in mid-course of disease - Frontalis sling recommended when levator function is very poor - Repeat surgery often needed due to progressive weakness - Reference: Codère F, 1993; Wong OG et al., 2013

2. Cricopharyngeal Myotomy - NCIT term: NCIT:C15329 - Effective for cricopharyngeal dysfunction (dysphagia) - Improves swallowing and reduces aspiration risk - Can be performed endoscopically or open - Reference: Périé S et al., 1997; Coiffier L et al., 2006

3. Botulinum toxin injection to cricopharyngeal muscle - Less invasive alternative for cricopharyngeal dysfunction - Temporary benefit; needs repeated injections - NCIT term: NCIT:C15986 (Pharmacotherapy) with therapeutic agent botulinum toxin

4. Gastrostomy tube placement - NCIT term: NCIT:C15329 - For severe dysphagia and malnutrition/aspiration - Reserved for advanced disease

Supportive Care

Dietary modifications: - Texture-modified diets (soft, pureed) - Thickened liquids to reduce aspiration - Upright positioning during meals - Small, frequent meals

Speech and swallowing therapy: - NCIT term: NCIT:C159273 (speech therapy) - Swallowing exercises, compensatory strategies

Physical therapy: - NCIT term: NCIT:C15302 (Physical Therapy) - Maintenance of strength and mobility

Nutritional support: - NCIT term: NCIT:C15433 (Nutritional Support) - Prevention of malnutrition

Experimental Therapies

1. Gene therapy approaches: - AAV-mediated PABPN1 silencing + replacement (BB-301) — under development by Benitec Biopharma; Phase 1/2 trials underway (NCT06185673) - Reference: Malerba A et al., 2017, PMID: 28829434; Trollet C et al., 2010

2. Autologous myoblast transplantation: - Injection of autologous satellite-cell-derived myoblasts into pharyngeal muscles (from unaffected muscles) — Phase 1/2 completed - Trial: NCT00773227 - Reference: Périé S et al., 2014, PMID: 24975581

3. Trehalose (autophagy-enhancing disaccharide): - Enhances autophagy and reduces PABPN1 aggregates in preclinical models - Phase 2 trial (NCT02015481) completed - Reference: Argov Z et al., 2016; Davies JE et al., 2006

4. Antisense oligonucleotides (ASO): - Preclinical; targeting PABPN1 or reducing GCN-expanded transcripts

5. Small molecule aggregation inhibitors: - Guanabenz, doxycycline, cystamine — investigated in preclinical models

Pharmacogenomics

• Not applicable (no pharmacological therapies currently proven effective)

Treatment Algorithm

1. Early symptomatic phase: Watchful monitoring; genetic counseling
2. Symptomatic ptosis: Ptosis surgery when interfering with vision
3. Symptomatic dysphagia: Diet modifications → speech/swallow therapy → botulinum toxin → cricopharyngeal myotomy
4. Advanced dysphagia: Consider gastrostomy
5. Progressive weakness: Physical therapy, assistive devices, mobility aids
6. Consider enrollment in clinical trials (gene therapy)

13. Prevention

Primary Prevention

• Genetic counseling — NCIT:C15240 (Genetic Counseling)
• Preimplantation genetic diagnosis (PGD) for at-risk couples
• Prenatal testing for known familial mutations

Secondary Prevention (early detection)

• Cascade genetic testing of at-risk relatives after proband diagnosis
• Not amenable to population-based screening (rare, adult-onset)

Tertiary Prevention (complications)

• Aspiration prevention: Diet modification, swallowing therapy, positioning
• Nutritional monitoring: Prevent malnutrition
• Fall prevention: Physical therapy, home safety
• Regular ophthalmological monitoring: Timely ptosis surgery
• Pulmonary hygiene: Prevent recurrent aspiration pneumonia

Immunization

• Pneumococcal and influenza vaccination recommended to prevent respiratory complications from aspiration

Counseling

• Genetic counseling — assessment of recurrence risk (50% for offspring of affected individuals in autosomal dominant form)
• Discussion of family planning options (PGD, prenatal diagnosis, adoption, gamete donation)

14. Other Species / Natural Disease

Taxonomy

• Homo sapiens (NCBI Taxon: 9606) — Only natural disease host

Natural Disease in Other Species

• No naturally occurring OPMD has been reported in animals.
• OPMD is a unique human disorder related to the specific PABPN1 polyalanine expansion mutation, which is not found in animal populations naturally.

Comparative Biology

• PABPN1 gene is highly conserved across vertebrates.
• Ortholog identifiers:
• Mouse (Mus musculus): Pabpn1 (NCBI Gene: 54196; MGI:1858245)
• Rat (Rattus norvegicus): Pabpn1
• Zebrafish (Danio rerio): pabpn1
• Drosophila: dPABP2

Evolutionary Conservation

• Poly(A) tail regulation is a fundamental cellular process conserved across eukaryotes.
• The polyalanine tract of PABPN1 is present in mammals but shorter in some species.

Transmission

• Not applicable (non-infectious genetic disease)

15. Model Organisms

Mouse Models

1. A17.1 transgenic mouse (also called A17) - Expresses bovine PABPN1 with expanded 17-alanine tract in skeletal muscle under human alpha-actin promoter - Phenotype: Progressive muscle weakness, intranuclear PABPN1 aggregates, altered mRNA processing - Reference: Davies JE et al., 2005, PMID: 15928288 - MGI: Available through Jackson Laboratory - Recapitulates: INI formation, muscle atrophy, molecular signatures of OPMD - Limitations: Overexpression model; not physiological expression level

2. Pabpn1-A17 knock-in mouse - Physiological expression of expanded PABPN1 - More faithful model of disease - Reference: Trollet C et al., 2010, PMID: 20876750

3. Pabpn1+/- heterozygous knockout - Models partial loss of function - Reference: Anvar SY et al., 2013

Cell Models

1. C2C12 mouse myoblasts with expPABPN1 expression - Recapitulate INI formation and cellular pathology - Reference: Abu-Baker A et al., 2003, PMID: 14507991; Wang Q et al., 2020, PMID: 32348770

2. Patient-derived myoblasts and iPSCs - Reference: Périé S et al., 2006; Raz V et al., 2013

Drosophila Models

Drosophila melanogaster (fruit fly) expressing expanded human PABPN1 - Displays progressive muscle degeneration - Widely used for genetic screening of modifiers - Reference: Chartier A et al., 2006, PMID: 16829879 - FlyBase: N/A (transgenic construct)

C. elegans Models

• Expanded polyalanine PABPN1 expressed in muscle causes muscle dysfunction
• Useful for large-scale genetic screens
• WormBase

Zebrafish Models

• Morpholino knockdown of pabpn1 causes muscle developmental defects
• Reference: Bhattacharya A et al., 2012

iPSC-Derived Models

• Patient-derived iPSCs differentiated into skeletal myotubes recapitulate cellular pathology (INIs, RNA processing defects)
• Reference: Raz V et al., 2013

Applications

• Testing therapeutic candidates (gene therapy, small molecules, chaperones, autophagy modulators)
• Investigating aggregate biology
• Testing ASO approaches
• Modeling age-dependent progression

Model Databases

• MGI: Mouse Genome Informatics — http://www.informatics.jax.org/
• IMPC: International Mouse Phenotyping Consortium
• FlyBase, WormBase, ZFIN
• Alliance of Genome Resources

Key References Summary

Ontology Term Recommendations Summary

Phenotype (HPO): - HP:0000508 Ptosis - HP:0002015 Dysphagia - HP:0003701 Proximal muscle weakness - HP:0000602 Ophthalmoplegia - HP:0000544 External ophthalmoplegia - HP:0001618 Dysphonia - HP:0000198 Tongue atrophy - HP:0011951 Aspiration pneumonia - HP:0001824 Weight loss - HP:0003722 Neck flexor weakness - HP:0003798 Rimmed vacuoles

Gene/Protein (HGNC): - hgnc:8565 PABPN1

Cell types (CL): - CL:0000188 Skeletal muscle cell - CL:0008002 Skeletal muscle fiber - CL:0000594 Satellite cell

Anatomy (UBERON): - UBERON:0001134 Skeletal muscle tissue - UBERON:0011115 Levator palpebrae superioris - UBERON:0006496 Cricopharyngeal muscle - UBERON:0001571 Pharyngeal constrictor muscles - UBERON:0001723 Tongue - UBERON:0001377 Quadriceps femoris - UBERON:0002048 Lung - UBERON:0001043 Esophagus

Biological process (GO): - GO:0006378 mRNA polyadenylation - GO:0016604 Nuclear body - GO:0016607 Nuclear speck - GO:0006914 Autophagy - GO:0006915 Apoptosis - GO:0043523 Regulation of neuron apoptotic process (analog)

Cellular component (GO): - GO:0005634 Nucleus - GO:0016607 Nuclear speck - GO:0005737 Cytoplasm - GO:0030017 Sarcomere

Disease (MONDO): - MONDO:0008116 Oculopharyngeal muscular dystrophy

Treatments (NCIT): - NCIT:C15329 Surgical Procedure - NCIT:C15986 Pharmacotherapy - NCIT:C15302 Physical Therapy - NCIT:C159273 Speech Therapy - NCIT:C15240 Genetic Counseling - NCIT:C15433 Nutritional Support - NCIT:C15238 Gene Therapy - NCIT:C15289 Organ Transplantation (myoblast transplant, related)

Taxonomy: - NCBITaxon:9606 Homo sapiens - NCBITaxon:10090 Mus musculus (mouse model) - NCBITaxon:7227 Drosophila melanogaster - NCBITaxon:6239 Caenorhabditis elegans - NCBITaxon:7955 Danio rerio (zebrafish)

Environmental (ECTO): - Not applicable (no established environmental factors)

Report compiled 2026-09-11 for use in the Disorder Mechanisms Knowledge Base (dismech). All ontology terms and PMIDs should be verified via authoritative sources before curation.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMID:9462747 (abstract only): "Short (GCG)8-13 expansions of a (GCG)6 repeat in the PABP2 gene cause autosomal dominant oculopharyngeal muscular dystrophy (OPMD), whereas a longer (GCG)7 allele acts as a recessive mutation"
• closest text in source: "Autosomal dominant oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disease with a world-wide distribution"

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• PMID:27831907 (1 mention) - Randomised crossover trial of rate feedback and force during chest compressions for paediatric cardiopulmonary resuscitation.
• shared terms: none
• PMID:10023876 (1 mention) - Evaluation of vaginal introital sampling as an alternative approach for the detection of genital Chlamydia trachomatis infection in women.
• shared terms: none
• PMID:20876750 (2 mentions) - Time trends of syphilis and HSV-2 co-infection among men who have sex with men in the German HIV-1 seroconverter cohort from 1996-2007.
• shared terms: none
• PMID:8580435 (3 mentions) - Hyaluronectin binds to laminin and blocks laminin-dependent process formation by astrocytes.
• shared terms: none
• PMID:15721219 (1 mention) - Increased facilitation of the primary motor cortex following 1 Hz repetitive transcranial magnetic stimulation of the contralateral cerebellum in normal humans.
• shared terms: none
• PMID:21929762 (1 mention) - An open pilot study of zonisamide augmentation in major depressive patients not responding to a low dose trial with duloxetine: preliminary results on tolerability and clinical effects.
• shared terms: none
• PMID:30760777 (1 mention) - Attenuated Lymphatic Proliferation Ameliorates Diabetic Nephropathy and High-Fat Diet-Induced Renal Lipotoxicity.
• shared terms: protein
• PMID:28829434 (1 mention) - ForCenS, a curated database of planktonic foraminifera census counts in marine surface sediment samples.
• shared terms: none
• PMID:24975581 (1 mention) - A melanin-independent interaction between Mc1r and Met signaling pathways is required for HGF-dependent melanoma.
• shared terms: model, protein

Weighed against this report's own most characteristic terms: pabpn1, muscle, disease, opmd, ptosis, dysphagia, genetic, expansion, progressive, aspiration, weakness, gene, model, protein, onset, expanded, cricopharyngeal, dominant, function, impaired.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0000198 (2 mentions) - the report calls it "Tongue atrophy"; HP calls it Absence of Stensen duct
• HP:0003798 (2 mentions) - the report calls it "rimmed vacuoles"; HP calls it Nemaline bodies
• UBERON:0004264 (1 mention) - the report calls it "skeletal muscle of trunk / eye"; UBERON calls it lower leg skin
• GO:0005634 (3 mentions) - the report calls it "nucleus", "site of PABPN1 intranuclear inclusions"; GO calls it nucleus
• GO:0016607 (3 mentions) - the report calls it "normal PABPN1 localization is disrupted"; GO calls it nuclear speck
• GO:0005737 (2 mentions) - the report calls it "rimmed vacuoles containing autophagic material"; GO calls it cytoplasm
• GO:0030017 (2 mentions) - the report calls it "progressive disruption"; GO calls it sarcomere
• GO:0005739 (1 mention) - the report calls it "secondary dysfunction"; GO calls it mitochondrion

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

• UBERON:0011115 (2 mentions) - UBERON does not contain this term

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0006378 (obsolete mRNA polyadenylation) (2 mentions)

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0000317 (1 mention) - the report calls it "Facial hypotonia"; HP calls it Facial myokymia
• GO:0006915 (2 mentions) - the report calls it "Apoptosis"; GO calls it apoptotic process, and lists "apoptosis" among its other names
• CL:0000188 (2 mentions) - the report calls it "skeletal muscle cell"; CL calls it cell of skeletal muscle, and lists "skeletal muscle cell" among its other names
• CL:0000594 (2 mentions) - the report calls it "satellite cell"; CL calls it skeletal muscle satellite cell
• NCIT:C159273 (2 mentions) - the report calls it "speech therapy"; NCIT calls it Speech Language Therapy

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• ORPHA:270 - called "autosomal dominant", "recessive"
• GO:0005634 - called "nucleus", "site of PABPN1 intranuclear inclusions"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, MGI.